Dr. Hudson Appointed to National Research Institute’s Advisory Panel

Matthew F. Hudson, Ph.D., M.P.H. will inform guiding institute’s patient-centered research efforts

PHILADELPHIA, PA — Matthew F. Hudson, PhD, MPH, NRG Oncology Cancer Care Delivery Research (CCDR) Vice Chair, has been appointed by the Patient-Centered Outcomes Research Institute (PCORI) as a member of its Advisory Panel on Patient Engagement.

Dr. Hudson will join other members of the panel in applying his experience and expertise to helping PCORI refine and prioritize the research it funds. He will also ensure that the research PCORI supports centers on the outcomes that matter to patients and other healthcare decision makers. PCORI is an independent, nonprofit organization authorized by Congress to fund research that will provide patients, their caregivers and clinicians with the evidence-based information needed to make better-informed healthcare decisions.

Dr. Hudson was selected on the basis of his experience, expertise and ability to contribute to the panel’s mission. Panel members represent a broad range of healthcare stakeholder groups and perspectives, including patients, family caregivers, clinicians, drug and device makers and researchers, among others.

Dr. Hudson states, “This Advisory Panel is a fabulous opportunity to partner with patients, thus ensuring research like CCDR identifies the salient patient factors driving outcomes and well-being. NRG Oncology is fortunate to have a cadre of engaged patients informing concept development. I think my appointment will provide insights I can use to inform our evolving patient engagement efforts in CCDR and other domains of the NRG Oncology portfolio.”

More information about the Advisory Panel on Patient Engagement, including its scope of work and a list of all members, is available on the PCORI website.

www.nrgoncology.org

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the NSABP Foundation, the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located worldwide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.